University of Miami's 2nd Biennial Miami Leukemia Symposium
- AML Biology and Treatment
- MDS Biology and Treatment
- ALL Biology and Treatment
- CLL Therapy in 2019
- CML and MPNs: Final Frontiers and New Breakthroughs
- Myeloid Biology and Novel Therapies
- Event
Playback speed
10 seconds
Magrolimab (Formerly 5F9) is a First-in-class Macrophage Immune Checkpoint Inhibitor Targeting CD47 in R/R AML
168 views
May 14, 2020
Comments 0
Login to view comments.
Click here to Login
MDS Biology and Treatment